Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy

Trial Profile

A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab sarotalocan (Primary) ; Cetuximab; Docetaxel; Methotrexate; Paclitaxel
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms LUZERA-301
  • Sponsors Aspyrian Therapeutics; Rakuten Medical
  • Most Recent Events

    • 06 Mar 2024 According to a Rakuten Medical media release, company announced the completion of a $119 million Series E preferred stock financing, including $45 million in new capital and the conversion of $74 million of convertible promissory notes with accrued interest to accelerate its global Phase 3 study with the goal of achieving approval of ASP-1929 in US as soon as possible.
    • 22 Jan 2024 According to a Rakuten Medical media release, company announced that the first patient in India received study treatment in August 2023. In India, 6 leading medical institutions are currently participating in this trial. Dr. Subramania Iyer K., is an investigator for the this study at the Amrita Institute of Medical Sciences and Research Centre (Kochi).
    • 18 Jul 2023 According to a Rakuten Medical media release, the company will host a virtual R&D Day to provide update from this trial; The webinar will take place on Thursday, August 10, 2023 at 8:30 AM PT / 11:30 AM ET; A live question and answer session will follow the formal presentation. Parties interested in participating in this event should click here to register and access the live webcast
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top